Tesamorelin is a peptide medicine that encourages the to release . It is used for excess abdominal fat associated with a specific condition in adults with HIV. To picture its role, imagine sending a signal that changes how the body coordinates certain fat stores. That specific medical use does not make it a general treatment for ordinary belly fat or overall weight loss.
SOURCE REFERENCE
Mixing and dose chart
Current aggregated data suggests the following information:
Each row shows a separate source example for Tesamorelin.
Bacteriostatic water is a source assumption. Amounts and schedules are not independently verified or personal medical advice. Consult a qualified clinician.
Peptide per Vial (mg)
BAC water
Dose
U-100 syringe
Frequency
10 mg
2 mL
1 mg
20 UNITS
Once daily, 5 days per week for 12 weeks, followed by a 4 week off period.
20 mg
2 mL
1 mg
10 UNITS
Once daily, 5 days per week for 12 weeks, followed by a 4 week off period.
THE DOSING REFERENCE
Dosing instructions
Amounts, schedules, and preparation - organized and summarized from current aggregated data
Egrifta is indicated to reduce excess abdominal fat in adults with HIV and lipodystrophy. It is not a general weight-loss medicine, and that indication should not be generalized to ordinary belly fat. [37]
Mechanism, evidence and interpretation
It stimulates the to release , which increases downstream signaling and affects body composition.
Egrifta is indicated to reduce excess abdominal fat in adults with HIV and . It is not a general weight-loss medicine, and that indication should not be generalized to ordinary belly fat. [37]
Source mass amounts and schedules are retained. Reviewed syringe conversions use the stated preparation; unresolved conversions are labeled unavailable. Not personal medical advice. Consult a qualified clinician for decisions about personal use.
Separate a change in hormone concentration from a demonstrated improvement in symptoms or function. Record baseline endocrine status, exact molecular form, exposure and follow-up. Results in a defined hormone disorder do not establish the same benefit in healthy adults.
A modified GHRH analog
Tesamorelin is a synthetic of releasing hormone. It stimulates the and increases endogenous growth hormone signaling, with downstream effects involving . Its clinical development focused on excess visceral abdominal fat in adults living with HIV and . surrounds internal organs; it is different from the fat located just under the skin. This distinction is central to the outcome studied.
Tesamorelin is not simply another name for sermorelin, CJC-1295 or ipamorelin. Their relationship to the release system provides context, but their structures and clinical evidence differ. The prescription product history also matters. Current Egrifta have product-specific preparation instructions, which should not be transferred to a research vial merely because the active ingredient name appears similar.
From a pituitary signal to a fat endpoint
Tesamorelin activates the pathway rather than supplying directly. Growth hormone can influence how tissues handle stored energy, and provides another part of the downstream response. This creates a biological reason to investigate changes in , but a plausible pathway is not the same as a broad weight-loss claim. The were needed to determine whether the specific intervention changed the specific fat compartment in the selected patients.
Body weight can remain relatively stable while a particular fat compartment changes. That is why a visceral-fat endpoint must be distinguished from total weight reduction. Imaging-based measures of abdominal tissue can answer a question that a scale cannot. Likewise, reduced does not automatically prove fewer cardiovascular events or benefit in people with a different diagnosis. Each of those questions requires appropriately designed evidence.
Randomized trials in adults with HIV-associated abdominal fat accumulation found reductions in during tesamorelin treatment. The evidence concerns that clinical setting, including the participants' background treatment and the outcomes measured. A separate randomized study examined liver fat as well as visceral fat. These findings add detail to the metabolic discussion, but they should not be summarized as proof of an unrestricted body-recomposition treatment.
The current Egrifta WR prescribing information identifies the specific clinical use and includes limitations and monitoring considerations. Hormone exposure, glucose regulation, fluid-related effects and other patient factors require clinical attention. The label also contains -specific instructions. A directory's historical schedule may refer to a different preparation, so the product name, strength and current instructions must stay together. The existence of an approved tesamorelin product does not validate every alternative formulation or advertised purpose.
Semaglutide and tirzepatide are discussed through appetite and pathways, while tesamorelin acts through the release system. Their trial populations and primary outcomes differ. Comparing them solely by a marketing phrase such as fat loss conceals that difference. Read the indication and endpoint first, then the mechanism. This keeps a real, diagnosis-specific clinical benefit separate from a general claim about losing weight.
How the growth hormone system works
The system is a conversation between several organs. The , a small region at the base of the brain, sends signals to the . One signal, , encourages growth hormone release. Another, , restrains it. and related signals can also affect release. The pituitary does not normally produce one steady hormone level. It releases pulses, whose size and timing change with sleep, age, nutrition and other conditions. This explains why one isolated blood measurement can be difficult to interpret.
acts directly on some tissues and also encourages production of in the liver and elsewhere. These signals influence growth, protein turnover and the use of stored energy. The same network also affects blood glucose. A compound that raises a hormone measurement has therefore changed a real biological system, but the measurement alone cannot tell us whether someone became stronger, recovered from an injury, or lived longer. Those are separate outcomes that require separate studies.
It helps to distinguish three intervention points. A asks the to release hormone through the GHRH . A receptor reaches the release system through a different receptor. An analog acts further downstream, rather than simply asking the pituitary to work harder. These differences matter when comparing sermorelin, ipamorelin and IGF-1 LR3. Similar marketing descriptions do not make these substances interchangeable.
Feedback also matters. Circulating hormones can reduce further stimulation, and can change their response during repeated exposure. A stronger initial response does not guarantee a stronger continuing benefit. Body composition measurements need careful reading too: includes water and other nonfat tissues, not just contractile muscle. A trial should therefore report functional outcomes, such as measured strength or walking ability, alongside hormone levels and body composition. Without that context, a biochemical change can sound much more useful than the evidence actually demonstrates.
Timing also changes what a measurement means. A peak concentration describes one moment, while overall exposure describes a period of time. Sampling immediately after a stimulus can produce a different impression from sampling between pulses. Researchers may therefore use repeated blood draws rather than one isolated result. This does not make every high value desirable; it makes the interpretation more precise. For a release-pathway compound, the relevant question is how the intervention changes the pattern and whether that change produces an outcome that matters, compared with an appropriate control group.
How to read the research and dosing record
The dosing record above and this article serve different purposes. The record preserves source amounts and schedules. The article explains identity, biology and evidence. An archived schedule is not a clinically validated prescription, and a calculation cannot decide whether a compound is suitable for a person. Keep the exact molecule, , route and strength attached to any research claim. Do not treat an animal experiment as a human dosing instruction or transfer a prescription product's instructions to a different vial.
When checking a paper, first identify who or what was studied. Then check the comparison group, the measured outcome, the length of follow-up and reported adverse effects. A laboratory marker and a patient benefit are different endpoints. Small exploratory studies can help generate a hypothesis, while larger controlled studies can test it more reliably. Internal compound links provide comparisons, and the dotted terms open short definitions with links to the site's glossary. The source links below let you check the original context rather than relying on a headline.
Key facts
SOURCE DATA
Molecular formula
—
Molecular weight
—
CAS number
—
Sequence
—
Half-life
Approximately 11 minutes after a single 1.28-mg subcutaneous EGRIFTA WR dose in healthy subjects; formulation-specific.
Calculated doses are derived from the source UNITS and assume added liquid equals final volume. U-100 UNITS measure volume, not drug activity. Source UNITS may be rounded or differ from an explicit dose; see the detailed source protocol below.
Source reference for research and education. Not personal medical advice. Amounts and clinical suitability are not independently verified. Conversion checks are labeled below.
Source review note
Source-reported quantities and schedules are educational comparisons, not verified administration instructions. Route, diluent compatibility, vial capacity, final volume and clinical suitability are unverified. Added liquid is assumed to equal final volume only for arithmetic. U-100 UNITS measure volume; drug activity IU is a separate unit.
Source review note
Source-reported quantities and schedules are educational comparisons, not verified administration instructions. Route, diluent compatibility, vial capacity, final volume and clinical suitability are unverified. Added liquid is assumed to equal final volume only for arithmetic. U-100 UNITS measure volume; drug activity IU is a separate unit.
Research discussion 0
Share a source, ask a question, or add context. Every comment is reviewed before it appears publicly.
Explore the peptide forum → for dedicated threads and nested conversations.
Save your research and join the conversation.
Sign in to comment